Amy Tapper is a scientist with 20 years of industry experience. Dr. Tapper is Chief, Technical Operations for Imago BioSciences. Dr. Tapper manages all aspects of CMC for both drug substance and drug product, as well as supports all non-clinical development activities. Dr. Tapper is a founding employee of Imago.
Dr. Tapper began her career at Genzyme Drug Discovery and Development as a Staff Scientist in chemical process development. At Genzyme, she worked on several polymer and small molecule candidates. In 2004 she moved to Peptimmune as an Associate Director of CMC and technical program management. While at Peptimmune, she led the chemistry and development program for a Phase 1 anti-obesity candidate, and also managed the chemistry and manufacturing for several of their peptide therapies. In 2007, she moved to Momenta Pharmaceuticals as a Principal Scientist working on a novel anticoagulant compound for acute coronary syndrome in Phase 2 clinical trials.
Dr. Tapper joined Ferrokin BioSciences in 2007 as a founding employee and was Vice President of CMC and Non-Clinical until its acquisition by Shire Pharmaceuticals in April 2012.
Dr. Tapper received a Ph.D. in chemistry from Boston University and B.S. in chemistry from Boston College. She has been very active in the National American Chemical Society and also in the Northeastern Section of the American Chemical Society (NESACS). She was the chair of the NESACS in 2005.